News Celltrion, Inc.

Stocks

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 16/06/2026			5-day change	1st Jan Change
1,74,500.00 ^KRW	-0.29%		+2.65%	+1.23%

02/06	Celltrion Workers Form Labor Union	MT
21/05	Celltrion, Inc. authorizes a Buyback Plan.	CI

All News

Mentions Relevance

02/06	Celltrion Workers Form Labor Union	MT
21/05	Celltrion, Inc. authorizes a Buyback Plan.	CI
21/05	Celltrion, Inc. announces an Equity Buyback for 557,414 shares.	CI
21/05	Celltrion Inc to acquire 100 billion won worth of own shares	RE
15/05	Celltrion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
13/05	Celltrion USA, Inc. announced that it has received $516.1 million in funding from Celltrion, Inc.	CI
08/05	Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on April 22, 2026.	CI
06/05	Celltrion's Net Attributable Income Jumps 219% in Q1	MT
06/05	Celltrion to Retire KRW100 Billion Worth of Treasury Shares	MT
06/05	Celltrion Q1 operating profit 322 billion won, up 115% Y/Y	RE
06/05	Celltrion to cancel 100 billion won treasury shares	RE
06/05	Celltrion, Inc.'s Equity Buyback announced on April 22, 2026, has expired with 488,977 shares, representing 0.22% for KRW 99,999.87 million.	CI
30/04	Celltrion, Inc. agreed to acquire Gifrer Barbezat SAS.	CI
24/04	Celltrion plans phase 3 clinical trials for Keytruda biosimilar with 220 patients	RE
22/04	Celltrion, Inc. authorizes a Buyback Plan.	CI
22/04	Celltrion, Inc. announces an Equity Buyback for 492,611 shares.	CI
22/04	Celltrion to buy 100 billion won of own shares	RE
08/04	Nomura Adjusts Celltrion's Price Target to KRW270,000 From KRW240,000, Keeps at Buy	MT
24/03	Celltrion : Announces KRW 1.2Tn Expansion of New DS Production Facilities in Songdo; Adds 180,000L of DS capacity, bringing total capacity to 570,000L	PU
24/03	Celltrion to Build Two New Plants in Songdo Campus	MT
23/03	Worker Dies After Fatal Fall at Celltrion's Incheon Plant; Shares Decline 6%	MT
17/03	Celltrion Launches Anti-Inflammatory Drug Biosimilar in US; Shares Rise 3%	MT
17/03	Celltrion : signs supply agreement with a global biopharma worth up to KRW 375.4 billion, reflecting recognition of product quality and manufacturing productivity, and accelerating CDMO growth	PU
17/03	Celltrion Secures Pharmaceutical Manufacturing Contract; Shares Rise 3%	MT
16/03	Celltrion Inc Announces U S Availability Of AVTOZMA® (tocilizumab-anoh) Subcutaneous (SC) Formulation	CI